JAMA, the Journal of the American Medical Association. Bridget M. Kuehn, Feb 15th, 2012.
With more than 600 neurological diseases—many of them rare—under its purview, the National Institute of Neurological Disorders and Stroke (NINDS) faces unique challenges in translating the findings from basic research into clinical practice. Completing clinical trials at individual academic centers is not possible, as patient populations are often scattered across the country. Yet creating a temporary consortium of clinical sites for each new trial, the traditional approach to multicenter trials, can be slow and inefficient. Additionally, industry has been somewhat reluctant to fund clinical trials in this area, according to Petra Kaufmann, MD, PhD, a neurologist and director of the office of clinical research at NINDS.
A new clinical trial network will conduct trials on many neurological diseases, including neurological disorders that are rare. Read Full Article